Browse By

Tag Archives: Financials

James E. Wagner Cultivation Reports Fiscal First Quarter 2020 Financial Results

KITCHENER, Ontario, Feb. 21, 2020 (GLOBE NEWSWIRE) — James E. Wagner Cultivation Corporation (TSX VENTURE: JWCA; OTCQX: JWCAF), a premium cannabis brand focused on producing clean, consistent cannabis grown using its advanced and proprietary GrowthSTORM™ aeroponic platform, reported financial results for its fiscal first quarter ended December

The Valens Company to Hold Conference Call to Discuss Financial Results for the Fourth Quarter and Fiscal Year 2019

KELOWNA, BC, Feb. 20, 2020 /CNW/ – Valens GroWorks Corp. (TSXV: VLNS) (OTCQX: VLNCF) (the “Company“, “Valens” or “The Valens Company“), a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products, is pleased to announce it expects to issue its fourth quarter and fiscal year 2019 financial results,

48North Cannabis Corp. Announces Revenue Growth for Fiscal Q2 2020 and Provides Product Launch Update

TORONTO, Feb. 20, 2020 /CNW/ – 48North Cannabis Corp. (“48North” or the “Company”) (TSXV: NRTH), a leading licensed cannabis producer focused on low-cost cultivation, brand, and consumer-friendly cannabis products, has released its financial and operating results for the second quarter ended December 31, 2019. The Company’s financial statements and

Curaleaf to Report Fourth Quarter and Fiscal Year 2019 Financial and Operational Results

WAKEFIELD, Mass., Feb. 18, 2020 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading vertically integrated cannabis operator in the United States, today announced that it will report its financial and operating results for the fourth quarter and fiscal year ended December 31, 2019 after

InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

– Commenced Dosing of Patients in Phase 1 Clinical Trial with INM-755 – VANCOUVER, Feb. 14, 2020 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN;OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development

Canopy Rivers Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Corporate Update

TORONTO, Feb. 14, 2020 /PRNewswire/ – Canopy Rivers Inc. (the “Company” or “Canopy Rivers“) (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, today released its financial results for the three and nine months ended December 31, 2019 (“Q3 2020“). The Company’s unaudited condensed interim consolidated financial

Canopy Growth Reports Third Quarter Fiscal 2020 Financial Results

Generated $124 million Net Revenue, up from $76 million in Q2 2020Excluding portfolio restructuring charges in Q2 2020, Net Revenue up 13%Achieved Gross Margin of 34%Total Operating Expenses down 14% versus the prior quarterAdjusted EBITDA loss decreases to $92 million SMITHS FALLS, ON, Feb. 14, 2020 /CNW/ – Canopy Growth Corporation (“Canopy Growth”

Supreme Cannabis Announces Q2 2020 Financial Results and Updated Plan for Accelerated Revenue Growth

Focuses business on accelerated, near-term revenue growth with enhanced, coast-to-coast sales partnership with humble+fume Enhanced cost structure and near-term revenue generating opportunities expected to drive profitable growth Reports 17% year-over-year net revenue growth and maintains a strong liquidity position with total cash and restricted cash